Company Encyclopedia
View More
name
GARDEN BIOPHARMA
300401.SZ
Zhejiang Garden Biopharmaceutical Co.,Ltd. operates as a food additive and pharmaceutical manufacturing industry in China. The company provides lanolin cholesterol, vitamin A and AD3 particles, vitamin D3, 25-hydroxyvitamin D3, chemical drugs and Chinese patent medicines. It offers cholesterol; feed grade vitamin D3, refined lanolin; food additives compound nutrient fortifier SDS, CO, and MO; cholecalciferol; feed additive - vitamin D3 particles and oil; VD3 resin oil; 25 hydroxyvitamin D3 progen and powder; 25 hydroxyvitamin D3; anhydrous lanolin; wood oil; wool wax; low chroma pure fat; lanolin alcohol; isopropyl lanolate; lanolinic acid; high acid fat; wood acid biofuel/wood alcohol biofuel; and rodenticide made from Vitamin D3.
3.095 T
300401.SZMarket value -Rank by Market Cap -/-

Financial Score

26/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking113/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE9.20%B
    • Profit Margin24.31%A
    • Gross Margin54.57%B
  • Growth ScoreB
    • Revenue YoY9.43%B
    • Net Profit YoY5.94%C
    • Total Assets YoY6.92%B
    • Net Assets YoY8.82%B
  • Cash ScoreC
    • Cash Flow Margin411.33%C
    • OCF YoY9.43%B
  • Operating ScoreD
    • Turnover0.22D
  • Debt ScoreC
    • Gearing Ratio42.19%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    GARDEN BIOPHARMA released its performance for the first three quarters, with a net profit attributable to the parent company of 234 million yuan, a decrease of 3.07%

    According to the Zhitong Finance APP, GARDEN BIOPHARMA released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 936 million yuan, a year-on-year decrease of 0.20%. The net profit attributable to shareholders of the listed company was 234 million yuan, a year-on-year decrease of 3.07%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 221 million yuan, a year-on-year increase of 9.06%. The basic earnings per share were 0.43 yuan

    Zhitong·
    SZ
    300401
    -1.57%
    Zhitong·
    SZ
    300401
    -1.57%

    Zhejiang Garden Biopharma has completed the sale of shares under its 2022 employee stock ownership plan and will terminate it

    Zhejiang Garden Biopharma Co., Ltd. announced that all shares of the employee stock ownership plan for 2022 have been sold, involving 7,674,790 shares, accounting for 1.41% of the company's total share capital. The duration of the plan is 42 months, with two batches of unlocks, expiring on September 28, 2023, and September 28, 2024, respectively. The company will carry out subsequent asset liquidation and distribution and will terminate the plan as required

    Zhitong·
    SZ
    300401
    -1.57%
    Zhitong·
    SZ
    300401
    -1.57%

    GARDEN BIOPHARMA: Subsidiary obtains drug registration certificate

    GARDEN BIOPHARMA announced that its wholly-owned subsidiary, Zhejiang Garden Pharmaceutical Co., Ltd., has received the "Drug Registration Certificate" for "Alpha-Lipoic Acid Tablets" and "Bisoprolol Amlodipine Tablets" issued by the National Medical Products Administration. Alpha-Lipoic Acid Tablets are mainly used for the treatment of diabetic peripheral neuropathy, while Bisoprolol Amlodipine Tablets are primarily used for the treatment of hypertension. The acquisition of the drug registration certificates will further enrich the company's product line, promote the upgrade of product capabilities, and have a positive impact on the company's development

    Zhitong·
    SZ
    300401
    -1.57%
    Zhitong·
    SZ
    300401
    -1.57%

    The price of Vitamin D3 has shown a continuous upward trend

    According to market sources, recently, the supply of global vitamin D3 raw materials has been restricted, exacerbating the supply-demand conflict in the market, with prices showing a continuous upward trend. The domestic largest vitamin D3 manufacturer, Garden Biopharmaceutical, has seen domestic market prices reach 660 yuan/kg, setting a new high for this year's prices

    Zhitong·
    SZ
    300401
    -1.57%
    Zhitong·
    SZ
    300401
    -1.57%

    Garden Biopharmaceutical released its first-quarter performance, with a net profit attributable to the parent company of 96.5114 million yuan, a year-on-year increase of 5.5%

    Garden Biopharmaceutical released its Q1 2025 earnings report, with operating revenue of 326 million yuan, a year-on-year decrease of 1.18%; net profit attributable to the parent company of 96.5114 million yuan, a year-on-year increase of 5.5%; net profit after deducting non-recurring gains and losses of 88.1384 million yuan, a year-on-year increase of 44.42%; basic earnings per share of 0.18 yuan/share

    Zhitong·
    SZ
    300401
    -1.57%
    Zhitong·
    SZ
    300401
    -1.57%
    © 2025 Longbridge｜Disclaimer